Agenus | AGEN - Sales Revenues

Stock Price
3.01
Daily Change
-0.19 -5.94%
Monthly
2.38%
Yearly
28.09%
Q1 Forecast
3.23

Agenus reported $24.07M in Sales Revenues for its fiscal quarter ending in March of 2025.





Sales Change Date
AbbVie USD 16.62B 840M Dec/2025
Agenus USD 24.07M 2.77M Mar/2025
Amgen USD 9.9B 340M Dec/2025
AstraZeneca USD 15.5B 313M Dec/2025
Bristol-Myers Squibb USD 12.5B 300M Dec/2025
Celldex Therapeutics USD 121K 769K Dec/2025
CSL USD 8.33B 4.79B Dec/2025
Eli Lilly USD 19.3B 1.7B Dec/2025
Gilead Sciences USD 7.93B 130M Dec/2025
GlaxoSmithKline GBP 8.62B 73M Dec/2025
Glaxosmithkline GBP 11.52B 3.54B Sep/2025
Incyte USD 1.51B 140M Dec/2025
Intrexon USD 717K 511K Jun/2024
J&J USD 24.6B 610M Dec/2025
Jiangsu Hengrui CNY 7.43B 1.17B Sep/2025
Karyopharm Therapeutics USD 30.54M 8.24M Dec/2024
MacroGenics USD 72.84M 50.6M Sep/2025
Merck EUR 5.32B 890M Sep/2025
Merck USD 16.4B 880M Dec/2025
Northwest Biotherapeutics USD 445K 39K Dec/2023
Novartis USD 13.91B 144M Sep/2025
Novavax USD 84.51M 330.97M Sep/2024
Pfizer USD 17.58B 880M Dec/2025
Regeneron Pharmaceuticals USD 3.88B 130M Dec/2025
Rigel Pharmaceuticals USD 55.31M 18.47M Sep/2024
Sangamo BioSciences USD 356K 125K Jun/2024
Veracyte USD 140.6M 8.7M Dec/2025